http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102014025018-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_474dbed999f134bd1857153d4b20fc8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f861d7dfdde7b233339d4838364a8e8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 |
| filingDate | 2014-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b32d94a7f62880701c98c832df9c169e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dad43cfb20cef67e1c744389a126101 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc54d3a3441f56a188889c3e8e845b47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40e4471b3b31c7462a753afa5afaa53a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca30ccf3bb3ff8cc3b0d626483812909 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_691e7ea3c6ac4bfbe25636fe77c2ef02 |
| publicationDate | 2016-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102014025018-A2 |
| titleOfInvention | pharmaceutical compositions containing the halogenated metronidazole derivative for treatment of cavitary protozooses and uses |
| abstract | pharmaceutical compositions containing the halogenated metronidazole derivative for treatment of cavitary protozooses and uses. The present invention describes pharmaceutical compositions containing halogenated metronidazole derivative, preferably the chlorinated derivative, and the use of these derivatives for the treatment of trichomoniasis, preferably when caused by metronidazole-resistant trichomonas vaginalis strain, in addition to giardiasis, which is caused by giardia lamblia and amoebiasis, which is caused by entamoeba histolytica. The pharmaceutical compositions of the present invention for the treatment of trichomoniasis, giardiasis and / or amoebiasis comprise the halogenated derivative of metronidazole, preferably the chlorinated derivative, plus pharmaceutically and pharmacologically acceptable excipients. This chlorinated derivative showed inhibitory activity for trichomonas vagina / das of the order of nanomolar (cl 50 = 6nm), and in addition, cl 50 for g. lamblia and e. histolytica was smaller for the chlorinated analogue, thus being more efficient than metronidazole, which is the drug of choice for the treatment of infections by these protozoa. The use of such compounds at low concentrations due to low IC50 values, in addition to their low cytotoxicity and acute toxicity, should lead to less significant adverse effects and reduced resistance. |
| priorityDate | 2014-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.